Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Flerie ABFRA:1NP1 -5.94%38 EV-to-EBIT is -1.68 as of Sep. 03, 2026. GuruFocus rates FRA:1NP1 with a GF Score™ of 38/100. The stock has 1 warning sign investors should review. Among 365 Biotechnology companies, Flerie AB ranks worse than 273972.33% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Flerie AB's Enterprise Value for the quarter that ended in Jun. 2026 was €118.79 Mil.
Flerie AB's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-67.09 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Flerie AB EV-to-EBIT Related Terms
Flerie AB EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Flerie AB's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:1NP1 vs VRTX, REGN, MRNA: EV-to-EBIT Comparison
For the Biotechnology subindustry, Flerie AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Flerie AB EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Flerie AB's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Flerie AB's EV-to-EBIT falls into.
Flerie AB's current Enterprise Value is €112.66 Mil.
Flerie AB's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-67.09 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Flerie AB (FRA:1NP1) has a EV-to-EBIT of -1.68 as of Sep. 03, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Flerie AB and its competitors. According to the industry distribution chart, Flerie AB ranks #999999 out of 365 companies in the Biotechnology industry.
Is Flerie AB's EV-to-EBIT too high?
Flerie AB's current EV-to-EBIT is -1.68. Based on the distribution chart, Flerie AB ranks #999999 out of 365 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Flerie AB has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Flerie AB's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Flerie AB ranks #999999 out of 365 companies for EV-to-EBIT. This places Flerie AB in the lower half of its industry. The industry median EV-to-EBIT is 15.79. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.79, based on 365 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Flerie AB and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Flerie AB's current EV-to-EBIT is -1.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Flerie AB stock overvalued right now?
Flerie AB (FRA:1NP1) has a current EV-to-EBIT of -1.68. The current EV-to-EBIT is -1.68. Flerie AB's overall GF Score™ is 38/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Flerie AB (FRA:1NP1), the current EV-to-EBIT is -1.68 as of Sep. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Flerie AB is a pharmaceutical company focusing on immunological diseases with great medical needs for new treatment options. The portfolio of the company includes Immuno-Oncology, metabolic diseases, and biologics development and manufacturing organizations. It operates in two segments The Product Development segment, and The Commercial Growth segment. The Product Development segment consists of early and mid-stage biotech and pharma companies advancing their products and technologies toward clinical proofof-concept and marketing approvals. The Commercial Growth segment consists of companies already selling products or services, showcasing their ability to generate increasing revenues ahead of reaching sustainable profitability.
38GF Score
Get the complete analysis for FRA:1NP1
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:1NP1 has been successfully added to your 
